Antinol® PCSO-524® – The Executive Summary
Authors:
The Summary of the researches and publications on www.antinolstudies.com
PCSO-524® contains a unique combination of free fatty acids, sterol esters, polar lipids, and carotenoids, and has been shown to be a 5-lipoxygenase (LOX) and cyclooxygenase (COX-2) modulator providing a potent anti-inflammatory effect.
The majority of the research using PCSO-524® has been in support of its anti-inflammatory activity, particularly in arthritis, where it has been compared to non- steroidal anti-inflammatory drugs (NSAIDs) in several animal clinical trials.
Unique features of Antinol® / Point of difference
Antinol® contains PCSO-524® in combination with olive oil, and a small amount of vitamin E added as an antioxidant.
The manufacture and extraction process of PCSO-524® has been developed over many years and is covered by several international patents.
The stabilisation process and freeze drying of the mussels is conducted by Pharmalink International (PIL) shareholder and manufacturing partner MacLab and the extraction is completed in a state of the art facility owned by Pharmalink Extracts Limited. The patented PCSO-524® extract is sold in more than 40 countries around the world in soft-gel capsules, blister packed in aluminium foil, which are encapsulated and packaged by a number of GMP-approved facilities around the globe.
Antinol® clinical research – Osteoarthritis
There have been several clinical trials looking at efficacy in canine osteoarthritis of the hip, stifle, and shoulder joints, as well as its effect in the post-surgical treatment of animals undergoing joint surgery. These trials are outlined in the following section.
(1) PCSO-524 in Comparison the NSAID Carprofen for Treatment of Canine Osteoarthritis.
Thai Journal of Veterinary Medicine. 2016. 46(3): 363-371
(2) Effect of PCSO-524 on OA Biomarkers and Weight-bearing Properties in Canine Osteoarthritis.
Thai Journal of Veterinary Medicine 2015. 45(2): 157-165
(3) PCSO-524 for Treatment of Canine OA and Degenerative Spinal Disease.
Thai Journal of Veterinary Medicine. 2012. 42(3): 311-317
(4) PCSO-524 compared to the NSAID firocoxib for recovery post-surgery in canines undergoing medial patellar luxation repair.
Thai Journal of Veterinary Medicine. 2015. 45(4): 639-643
(5) PCSO-524 Compared to NSAID for Post-operative Recovery in Canines Undergoing Stifle Surgery.
Poster presentation – World Small Animal Veterinary Association 38th Annual Congress. 2013
(6) The Effectiveness of Marine Based Fatty Acid Compound (PCSO-524) and Firocoxib in the Treatment of Canine Osteoarthritis.
Beale et al. Poster Presentation Veterinary Orthopedic Society Conference, March 2018.
(7) The Effectiveness of Marine Based Fatty Acid Compound (PCSO-524) and Firocoxib in the Treatment of Canine Osteoarthritis.
Vijarnsorn et al. Veterinary Research: 2019. 15:349 http://doi.org/10.1186/s12917-019-2110-7
(8) The Clinical Study of PCSO-524 (Antinol®) as Neutraceutical in Canine Allergic Skin Disease.
Chaiyot et al. Oral Presentation at The World Veterinary Congress 2018.
Human clinical research – Osteoarthritis
There are seven human clinical trials that have been conducted in osteoarthritis using PCSO-524® or a pre-cursor Green-Lipped Mussel extract (GLMe), with a combined total of 368 OA patients. The trials are all slightly different in design and cover mild to severe OA.
However, the key areas of investigation across the studies support a reduction of pain and an increase in function with PCSO-524® supplementation.
(1) Pain relief for osteoarthritis of the knee and/or hip from PCSO-524 in comparison to fish oil. Rheumatologia. 2011. 49(4): 244-252
(2) Pain relief for osteoarthritis of the knee and/or hip from PCSO-524 in comparison to fish oil. International Journal of Pharmaceutical Sciences Review and Research. 2014. 27(1): 209-216
The Executive Summary also includes the section about Safety in Canine, Human OA studies, Research in laboratory animals, and In vitro research.